Dimenhydrinate vs Diphenhydramine for Motion Sickness
For motion sickness prevention, dimenhydrinate (Dramamine) is the preferred first-generation antihistamine based on FDA approval and specific dosing guidance for this indication, though both agents have comparable efficacy and side effect profiles.
Dosing
Dimenhydrinate (Dramamine)
- Adults and children ≥12 years: 50-100 mg every 4-6 hours (maximum 400 mg/24 hours)
- Children 6 to <12 years: 25-50 mg every 6-8 hours (maximum 150 mg/24 hours)
- Children 2 to <6 years: 12.5-25 mg every 6-8 hours (maximum 75 mg/24 hours)
- Timing: Take first dose 30-60 minutes before travel 1
Diphenhydramine (Benadryl)
- Adults: 25-50 mg every 4-6 hours (maximum 300 mg/24 hours)
- Timing: Several minutes onset, 4-6 hour duration 2, 3
- Note: Diphenhydramine lacks specific FDA labeling for motion sickness, though it has antihistaminic and anticholinergic properties similar to dimenhydrinate
Efficacy
Both agents are effective for motion sickness prevention under natural conditions. A 2022 Cochrane review found that first-generation antihistamines (including dimenhydrinate) prevented motion sickness symptoms in 40% of susceptible individuals versus 25% with placebo (RR 1.81,95% CI 1.23-2.66; moderate-certainty evidence) 4.
Dimenhydrinate specifically has been shown to:
- Reduce motion sickness symptom scores by an average of 5.9 points compared to placebo (p<0.001) 5
- Suppress gastric tachyarrhythmia associated with motion sickness 5
- Prevent development of abnormal gastric myoelectric activity during motion exposure 5
There are no head-to-head trials directly comparing diphenhydramine to dimenhydrinate for motion sickness. Both work through H1-receptor antagonism and anticholinergic effects 2, 6, 7.
Side Effects
Common to Both Agents
- Sedation: Most significant adverse effect. Antihistamines may cause sedation in 66% of users versus 44% with placebo (RR 1.51,95% CI 1.12-2.02) 4
- Anticholinergic effects: Dry mouth, blurred vision (14% vs 12.5% placebo), urinary retention, constipation 2, 3
- CNS effects: Dizziness, impaired cognition (though not significantly different from placebo at 29% vs 33%) 2, 4
- Cardiovascular: Hypotension 2, 3
Critical Performance Impairment Concerns
Dimenhydrinate causes significant psychomotor impairment. A 2001 study found that dimenhydrinate 100 mg significantly impaired decision reaction time and auditory digit span, with most subjects reporting decreased well-being and general performance abilities 8. This impairment can occur without subjective awareness of drowsiness 9.
Warning: First-generation antihistamines are associated with 1.5-fold increased risk of fatal automobile accidents and increased occupational accidents 9. Performance impairment persists beyond plasma half-life due to prolonged end-organ effects 9.
Formulation Differences
Slow-release formulations of dimenhydrinate (chewing gums with divided dosing) produce less sedation and CNS impairment than standard tablets while maintaining efficacy, likely due to slower CNS drug accumulation 10.
Clinical Algorithm
Step 1: Assess patient factors
- Age (children require weight-based dosing)
- Need for alertness (driving, operating machinery)
- Duration of travel
- Pregnancy status (both Category B, but avoid first trimester)
Step 2: Choose agent
- Dimenhydrinate: First choice due to FDA approval for motion sickness with clear dosing guidelines 1
- Diphenhydramine: Reasonable alternative if dimenhydrinate unavailable, using similar dosing
Step 3: Timing and administration
- Administer 30-60 minutes before motion exposure 1
- For prolonged travel, redose per schedule above
- Consider slow-release formulations if available to reduce sedation 10
Step 4: Counsel on safety
- Do not drive or operate machinery after taking either medication
- Avoid alcohol and other CNS depressants 2, 9
- Expect sedation even if not subjectively drowsy 9
- Watch for anticholinergic effects (dry mouth, urinary retention)
Important Caveats
- Neither agent should be used routinely for vertigo from other causes (e.g., BPPV), where repositioning maneuvers are superior 6
- Chronic high-dose use of dimenhydrinate has been associated with cognitive impairment and should be avoided 11
- Scopolamine may be superior for severe motion sickness, though comparison data are limited (very low-certainty evidence) 4
- No evidence supports use in children <2 years for dimenhydrinate 1
- Both agents work through similar mechanisms (H1-antagonism and anticholinergic effects), so switching between them is unlikely to improve efficacy or reduce side effects 12, 7